EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY-NC-ND 4.0

Protocol for the TRANSLATE prospective, multicentre, randomised clinical trial of prostate biopsy technique

Richard J Bryant iD, Hide Yamamoto iD, Ben Eddy, Sashi Kommu, Krishna Narahari, Altan Omer, Tom Leslie, James W F Catto, Derek J Rosario, Daniel W Good, Rob Gray, Matthew P C Liew und 17 weitere

BJU International · 2023

DOI: 10.1111/bju.15978 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BJU International, 2023. Verfasst von Richard J Bryant und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK. Hauptthemen laut MEDLINE: Prostate, Prostatic Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Primary objectives: to determine whether local anaesthetic transperineal prostate (LATP) biopsy improves the detection of clinically significant prostate cancer (csPCa), defined as International Society of Urological Pathology (ISUP) Grade Group ≥2 disease (i.e., any Gleason pattern 4 disease), compared to transrectal ultrasound‐guided (TRUS) prostate biopsy, in biopsy‐naïve men undergoing biopsy based on suspicion of csPCa. Secondary objectives: to compare (i) infection rates, (ii) health‐related quality of life, (iii) patient‐reported procedure tolerability, (iv) patient‐reported biopsy‐related complications (including bleeding, bruising, pain, loss of erectile function), (v) number of subsequent prostate biopsy procedures required, (vi) cost‐effectiveness, (vii) other histological parameters, and (viii) burden and rate of detection of clinically insignificant PCa (ISUP Grade Group 1 disease) in men undergoing these two types of prostate biopsy. Patients and Methods The TRANSLATE trial is a UK‐wide, multicentre, randomised clinical trial that meets the criteria for level‐one evidence in diagnostic test evaluation. TRANSLATE is investigating whether LATP biopsy leads to a higher rate of detection of csPCa compared to TRUS prostate biopsy. Both biopsies are being performed with an average of 12 systematic cores in six sectors (depending on prostate size), plus three to five target cores per multiparametric/bi‐parametric magnetic resonance imaging lesion. LATP biopsy is performed using an ultrasound probe‐mounted needle‐guidance device (either the ‘Precision‐Point’ or BK UA1232 system). TRUS biopsy is performed according to each hospital's standard practice. The study is 90% powered to detect a 10% difference (LATP biopsy hypothesised at 55% detection rate for csPCa vs 45% for TRUS biopsy). A total of 1042 biopsy‐naïve men referred with suspected PCa need to be recruited.

Conclusions

This trial will provide robust prospective data to determine the diagnostic ability of LATP biopsy vs TRUS biopsy in the primary diagnostic setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstateProstatic NeoplasmsMaleHumansProspective StudiesQuality of LifeBiopsyImage-Guided BiopsyMagnetic Resonance ImagingRandomized Controlled Trials as TopicMulticenter Studies as Topic

Stichwörter der Autor:innen

#PCSM#ProstateCancer#urooncProstate cancerclinically significant prostate cancerlocal anaesthetictransperineal prostate biopsytransrectal prostate biopsy

Autor:innen und Institutionen

  • Department of Urology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK.
  • Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
  • Department of Urology, Maidstone and Tunbridge Wells NHS Trust, Maidstone Hospital, Maidstone, UK.
  • Department of Urology, East Kent Hospitals University NHS Foundation Trust, Kent and Canterbury Hospital, Canterbury, UK.
  • Department of Urology, Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff, UK.
  • Department of Urology, University Hospitals Coventry and Warwickshire NHS Trust, University Hospital, Coventry, UK.

ORCID-Profile: Richard J Bryant, Hide Yamamoto, J Francisco Lopez, Alastair D Lamb

Förderung

  • Cancer Research UK

Zitieren

APA

Bryant, R. J., Yamamoto, H., Eddy, B., Kommu, S., Narahari, K., Omer, A., Leslie, T., Catto, J. W. F., Rosario, D. J., Good, D. W., Gray, R., Liew, M. P. C., Lopez, J. F., Campbell, T., Reynard, J. M., Tuck, S., Barber, V. S., Medeghri, N., Davies, L., …, & Lamb, A. D. (2023). Protocol for the TRANSLATE prospective, multicentre, randomised clinical trial of prostate biopsy technique. BJU International. https://doi.org/10.1111/bju.15978

Vancouver

Bryant RJ, Yamamoto H, Eddy B, Kommu S, Narahari K, Omer A, et al. Protocol for the TRANSLATE prospective, multicentre, randomised clinical trial of prostate biopsy technique. BJU International. 2023. doi:10.1111/bju.15978

BibTeX
@article{Bryant2023,
  author = {Bryant, Richard J and Yamamoto, Hide and Eddy, Ben and Kommu, Sashi and Narahari, Krishna and Omer, Altan and Leslie, Tom and Catto, James W F and Rosario, Derek J and Good, Daniel W and Gray, Rob and Liew, Matthew P C and Lopez, J Francisco and Campbell, Teresa and Reynard, John M and Tuck, Steve and Barber, Vicki S and Medeghri, Nadjat and Davies, Lucy and Parkes, Matthew and Hewitt, Aimi and Landeiro, Filipa and Wolstenholme, Jane and Macpherson, Ruth and Verrill, Clare and Marian, Ioana R and Williams, Roxanne and Hamdy, Freddie C and Lamb, Alastair D},
  title = {Protocol for the TRANSLATE prospective, multicentre, randomised clinical trial of prostate biopsy technique},
  journal = {BJU International},
  year = {2023},
  doi = {10.1111/bju.15978}
}
Kostenlos starten →